Advertisement

Pharmaceutical Research

, 36:149 | Cite as

Nano-Co-Delivery of Berberine and Anticancer Drug Using PLGA Nanoparticles: Exploration of Better Anticancer Activity and In Vivo Kinetics

  • Iliyas Khan
  • Gaurav Joshi
  • Kartik T Nakhate
  • Ajazuddin
  • Raj Kumar
  • Umesh GuptaEmail author
Research Paper

Abstract

Purpose

Combinatorial approach can be beneficial for cancer treatment with better patient recovery. Co-delivery of natural and synthetic anticancer drug not only valuable to achieve better anticancer effectivity but also to ascertain toxicity. This study was aimed to co-deliver berberine (natural origin) and doxorubicin (synthetic origin) utilizing conjugation/encapsulation strategy through poly (lactic-co-glycolic acid) (PLGA) nanoparticles.

Methods

Doxorubicin was efficiently conjugated to PLGA via carbodiimide chemistry and the PLGA-doxorubicin conjugate (PDC) was used for encapsulation of berberine (PDBNP).

Results

Significant anti-proliferative against MDA-MB-231 and T47D breast cancer cell lines were observed with IC50 of 1.94 ± 0.22 and 1.02 ± 0.36 μM, which was significantly better than both the bio-actives (p < 0.05). The ROS study revealed that the PDBNP portrayed the slight increase in the reactive oxygen species (ROS) pattern in MDA-MB-231 cell line in a dose-dependent manner, while in T47D cells, no significant change in ROS was seen. PDBNP exhibits significant alteration (depolarization) in mitochondrial membrane permeability and arrest of cell cycle progression at sub G1 phase while the Annexin V/PI assay followed by confocal microscopy resulted into cell death mode to be because of necrosis against MDA-MB-231 cells. In vivo studies in Sprague Dawley rats revealed almost 14-fold increase in half life and a significant increase in plasma drug concentration.

Conclusion

The overall approach of PLGA based co-delivery of doxorubicin and berberine witnessed synergetic effect and reduced toxicity as evidenced by preliminary toxicity studies.

Key Words

berberine encapsulation in vivo pharmacokinetics mitochondrial pathway necrosis PLGA-doxorubicin conjugate 

Abbreviations

AFM

Atomic force microscopy

DCM

Dichloromethane

EDC

1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide

hPBMCs

Human Peripheral Blood Mononuclear Cells

NHS

N-hydroxy succinimide

PDBNP

Berberine loaded PLGA-doxorubicin nanoparticles

PDC

PLGA-doxorubicin conjugate

PLGA

Poly lactide-co-glycolide

PNP

Blank nanoparticle

PVA

Polyvinyl alcohol

RBCs

Red blood cells

ROS

Reactive oxygen species

SEM

Scanning electron microscopy

Notes

ACKNOWLEDGMENTS AND DISCLOSURES

The authors would like to acknowledge the financial support received from Department of Science and Technology and University Grants Commission, New Delhi, India to Dr. Umesh Gupta in the form of DST Start up Research Grant (for Young Scientists). The first author (IK) also would like to acknowledge Indian Council of Medical Research (ICMR), New Delhi (Award letter no. 45/12/2018-Nan/BMS) for providing Senior Research Fellowship (SRF). GJ thanks CSIR, New Delhi (Grant no. 05/1051(0011)/2018-EMR-I) for providing SRF. The authors declare no competing financial interest. The authors would also like to acknowledge the Central Instrumentation Laboraory Central University of Punjab for extending facilities to carry out microscopy.

Supplementary material

11095_2019_2677_MOESM1_ESM.docx (695 kb)
ESM 1 (DOCX 694 kb)

References

  1. 1.
    Shim G, Kim MG, Kim D, Park JY, Oh YK. Nanoformulation-based sequential combination cancer therapy. Adv Drug Deliv Rev. 2017;115:57–81.CrossRefGoogle Scholar
  2. 2.
    Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev. 2016;98:19–34.CrossRefGoogle Scholar
  3. 3.
    Gautam CS, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol. 2008;65:795–6.CrossRefGoogle Scholar
  4. 4.
    Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol. 2011;12:1032–44.CrossRefGoogle Scholar
  5. 5.
    Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today. 2012;17:1044–52.CrossRefGoogle Scholar
  6. 6.
    Qi SS, Sun JH, Yu HH, Yu SQ. Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy. Drug Delivery. 2017;24:1909–26.CrossRefGoogle Scholar
  7. 7.
    Kemp JA, Shim MS, Heo CY, Kwon YJ. “Combo” nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv Drug Deliv Rev. 2016;98:3–18.CrossRefGoogle Scholar
  8. 8.
    Kleibl Z, Kristensen VN. Women at high risk of breast cancer: molecular characteristics, clinical presentation and management. Breast. 2016;28:136–44.CrossRefGoogle Scholar
  9. 9.
    Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21:968–75.CrossRefGoogle Scholar
  10. 10.
    Henderson IC, Berry DA, Demetri GD, Goldstein LJ, Martino S, Ingle JN, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–83.CrossRefGoogle Scholar
  11. 11.
    Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, et al. RNA expression of breast cancer resistance protein, lung resistance related protein, multi-drug resistance gene-1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res. 2003;9:827–36.PubMedGoogle Scholar
  12. 12.
    Anitha A, Maya S, Deepa N, Chennazhi KP, Naira SV, Tamura H, et al. Efficient water-soluble O-carboxymethyl chitosan nanocarrier for the delivery of curcumin to cancer cells. Carbohydr Polym. 2011;83:452–61.CrossRefGoogle Scholar
  13. 13.
    Murugan C, Rayappan K, Thangam R, Bhanumathi R, Shanthi K, Vivek R, et al. Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy. Sci Rep. 2016;6:34053.CrossRefGoogle Scholar
  14. 14.
    Gupta L, Sharma AK, Gothwal A, Khan MS, Khinchi MP, Qayum A, et al. Dendrimer encapsulated and conjugated delivery of berberine: a novel approach mitigating toxicity and improving in vivo pharmacokinetics. Int J Pharm. 2017;528:88–99.CrossRefGoogle Scholar
  15. 15.
    Ebrahimian M, Taghavi S, Ghoreishi M, Sedghi S, Farzad SA, Ramezani M, et al. Evaluation of efficiency of modified polypropylenimine (PPI) with alkyl chains as non-viral vectors used in co-delivery of doxorubicin and TRAILplasmid. AAPS Pharm Sci Tech. 2017;19:31029–36.Google Scholar
  16. 16.
    Han Y, Zhang P, Chen Y, Sun J, Kong F. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy. Int J Mol Med. 2014;34(1):191–6.CrossRefGoogle Scholar
  17. 17.
    Khan I, Gothwal A, Sharma AK, Kesharwani P, Gupta L, Iyer AK, et al. PLGA nanoparticles and their versatile role in anticancer drug delivery. Cri Rev Ther Drug Carr Sys. 2016;33(2):159–93.CrossRefGoogle Scholar
  18. 18.
    Khan I, Gothwal A, Sharma AK, Qayum A, Singh SK, Gupta U. Biodegradable nano-architectural PEGylated approach for the improved stability and anticancer efficacy of bendamustine. Int J Bio Macromol. 2016;92:1242–51.CrossRefGoogle Scholar
  19. 19.
    Desgouilles S, Vauthier C, Bazile D, Vacus J, Grossiord JL, Veillard M, et al. The design of nanoparticles obtained by solvent evaporation: a comprehensive study. Langmuir. 2003;19(22):9504–10.CrossRefGoogle Scholar
  20. 20.
    Malvern. ISO13320 2009. Particle Size Analysis - Laser Diffraction Methods, Part 1: General Principles.Google Scholar
  21. 21.
    Pamunuwa G, Karunaratne V, Karunaratne DN. Effect of lipid composition on in vitro release and skin deposition of curcumin encapsulated liposomes. J Nanomaterials. 2016:1–9.CrossRefGoogle Scholar
  22. 22.
    Ahmad A, Fauzia E, Kumar M, Kumar R. Gelatin-coated Polycaprolactone nanoparticle-mediated Naringenin delivery rescue human mesenchymal stem cells from oxygen glucose deprivation-induced inflammatory stress. ACS Biomater Sci Eng. 2019;5(2):683–95.CrossRefGoogle Scholar
  23. 23.
    Kumar H, Gothwal A, Khan I, Nakhate KT, Alexander A. Ajazuddin, et al. galactose anchored gelatin nanoparticles for primaquine delivery and improved pharmacokinetics: a biodegradable and safe approach for effective anti-plasmodial activity against P. falciparum 3D7 and in vivo hepatocytes targeting. Mol Pharm. 2017;14:3356–69.CrossRefGoogle Scholar
  24. 24.
    Chin DL, Lum BL, Sikic BI, et al. Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. J Chromato B. 2002;779:259–69.CrossRefGoogle Scholar
  25. 25.
    Tsai PL, Tsai TH. HPLC determination of berberine in medicinal herbs and a related traditional chinese medicine. Analytical Lett. 2002;35(15):2459–70.CrossRefGoogle Scholar
  26. 26.
    Agarwal GU, Jain NK. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials. 2007;28:3349–59.CrossRefGoogle Scholar
  27. 27.
    Singhai AK, Jain S, Jain NK. Evaluation of an aqueous injection of Ketoprofen. Pharmazie. 1997;52:149–51.PubMedGoogle Scholar
  28. 28.
    Jain AK, Thanki K, Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity. Mol Pharm. 2013;10:3459–74.CrossRefGoogle Scholar
  29. 29.
    Yoo HS, Lee KH, Oh JE, Park TG. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release. 2000;68:419–31.CrossRefGoogle Scholar
  30. 30.
    Wanga X, Wanga Q, Liua Z, Zheng X. Preparation, pharmacokinetics and tumour-suppressive activity of berberine liposomes. J Pharm Pharmacol. 2017;69:625–32.CrossRefGoogle Scholar
  31. 31.
    Fan X, Wang X, Cao M, Wang C, Hu Z, Wu Y-L, et al. “Y”-shape armed amphiphilic star-like copolymers: design, synthesis and dual-responsive unimolecular micelle formation for controlled drug delivery. Polym Chem. 2017;8:5611–20.CrossRefGoogle Scholar
  32. 32.
    Langdon SP. Cancer cell culture, methods and protocols, methods in molecular medicine, Humana Press, 2004.Google Scholar
  33. 33.
    Meerloo JV, Kaspers GL, Cloos J. Cell sensitivity assays: the MTT assay. Cancer Cell Culture. 2011:237–45.Google Scholar
  34. 34.
    Maksimenkoa A, Dosiob F, Mougina J, Ferrerob A, Wacka S, Reddya LH, et al. A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties. Proc Natl Acad Sci. 2014;111(2):E217–26.CrossRefGoogle Scholar
  35. 35.
    Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28:869–76.CrossRefGoogle Scholar
  36. 36.
    Diogo CV, Machado NG, Barbosa IA, Serafim TL, Burgeiro A, Paulo J. Berberine as a promising safe anti-Cancer agent-is there a role for mitochondria? Oliveira. Curr Drug Targets. 2011;12:850–9.CrossRefGoogle Scholar
  37. 37.
    Schneckenburger H, Stock K, Lyttek M, Strauss WS, Sailer R. Fluorescence lifetime imaging (FLIM) of rhodamine 123 in living cells. Photochem Photobiol Sci. 2004;3:127–31.CrossRefGoogle Scholar
  38. 38.
    Borodina VM, Zelenin AV. Fluorescence microscopy demonstration of mitochondria in tissue culture cells using berberine. Tsitologiia. 1977;19:1067–8.PubMedGoogle Scholar
  39. 39.
    Pereira CV, Machado NG, Oliveira PO. Mechanisms of Berberine (natural yellow 18)-induced mitochondrial dysfunction: interaction with the adenine nucleotide translocator. Toxicological Sci. 2008;105(2):408–17.CrossRefGoogle Scholar
  40. 40.
    Lüpertz R, Wätjen W, Kahl R, Chovolou Y. Dose and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology. 2010;271:115–21.CrossRefGoogle Scholar
  41. 41.
    Mahmoudi M, Azadmanesh K, Shokrgozar MA, Journeay WS, Laurent S. Effect of nanoparticles on the cell life cycle. Chem Rev. 2011;111:3407–32.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmacy, School of Chemical Sciences and PharmacyCentral University of RajasthanAjmerIndia
  2. 2.Department of Pharmaceutical Sciences and Natural Products, School of Basic and Applied SciencesCentral University of PunjabBathindaIndia
  3. 3.Rungta College of Pharmaceutical Science and ResearchBhilaiIndia

Personalised recommendations